Search company, investor...
Search

Total Raised

$21.71M

Investors Count

14

Pin Therapeutics Funding, Pin Therapeutics Valuation & Pin Therapeutics Revenue

3 Fundings

Pin Therapeutics's latest funding round was a Series B for $16.76M on February 21, 2022.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/21/2022

Series B

$16.76M

0

FY undefined

1

8/28/2019

Series A

$99M

0

FY undefined

10

12/1/2017

Incubator/Accelerator

0

FY undefined

10

Date

2/21/2022

8/28/2019

12/1/2017

Round

Series B

Series A

Incubator/Accelerator

Amount

$16.76M

$99M

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

Pin Therapeutics Investors

14 Investors

Pin Therapeutics has 14 investors. Korea Investment Partners invested in Pin Therapeutics's Series B funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

2/21/2022

2/21/2022

1
Series B

Venture Capital

South Korea

2/21/2022

2/21/2022

1
Series B

Venture Capital

South Korea

2/21/2022

2/21/2022

1
Series B

Diversified Financial Services

South Korea

00/00/0000

00/00/0000

Korea Development Bank

Subscribe to see more

Bank

South Korea

00/00/0000

00/00/0000

Loftyrock Investment

Subscribe to see more

Corporate Venture

South Korea

First funding

2/21/2022

2/21/2022

2/21/2022

00/00/0000

00/00/0000

Last Funding

2/21/2022

2/21/2022

2/21/2022

00/00/0000

00/00/0000

Investor

Korea Development Bank

Loftyrock Investment

Rounds

1
Series B
1
Series B
1
Series B

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Diversified Financial Services

Bank

Corporate Venture

Location

South Korea

South Korea

South Korea

South Korea

South Korea

You May Also Like

F
FIMECS

FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.

Arvinas Logo
Arvinas

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.

Kymera Therapeutics Logo
Kymera Therapeutics

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.

Nurix Therapeutics Logo
Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. The drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

C4 Therapeutics Logo
C4 Therapeutics

C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.